We have changed our domainWe have changed servers and operate Career|edu under a different domain. Our services will remain unchanged and we will continue to post the best career openings for the academic world at our new domain.
Go back to the Job List
Role of GPCRs and Beta-Arrestins in Type 2 Diabetes and ObesityPosted by: National Institutes of Health (NIH)
Posted date: 2020-Jan-10
A postdoctoral position is available to study the role of G protein-coupled receptor (GPCR)- and beta-arrestin-dependent signaling pathways in type 2 diabetes and obesity. The project involves the generation and analysis of new mouse models which express novel classes of designer GPCRs in a cell-type specific fashion (J Wess. Trends Endocrin Metab 27, 600-603, 2016). The use of these designer GPCRs makes it possible to activate distinct G protein- or beta-arrestin-dependent signaling pathways in a conditional and reversible fashion. Additional novel mouse models that lack distinct GPCRs or downstream signaling molecules including beta-arrestin-1 and -2 in a cell-type specific fashion will also be generated and analyzed.
The primary focus of the work will be on how GPCRs and beta-arrestins regulate the function of fat, liver, pancreatic alpha/beta cells, and certain types of neurons to maintain proper glucose and energy homeostasis. Mice will be analyzed by physiological (metabolic), pharmacological, molecular, and biochemical techniques. The ultimate goal is to identify molecular pathways through which GPCRs and GPCR-associated proteins contribute to the pathophysiology of type 2 diabetes and obesity.
For additional information, please visit: https://www.niddk.nih.gov/about-niddk/staff-directory/biography/w/wess-jurgen.Qualifications:
Background in mouse physiology/pharmacology and experience with genetically modified mice is required. Basic molecular biological and biochemical skills are also essential. The salary and benefits are as per NIH regulations commensurate with experience.To Apply:
Please send a cover letter with CV, bibliography, and names of three references (including e-mail addresses and telephone numbers) to jurgenwniddk.nih.gov. Tentative starting date: summer/early fall 2020.
For more information, please contact: Jurgen Wess, PhD, Chief, Molecular Signaling Section, LBC, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Building 8A, Room B1-A05, Bethesda, MD 20892, USA, Tel: (301) 402-3589; E-mail: jurgenwniddk.nih.gov.
The NIH is an equal opportunity employer. The NIH is dedicated to building a diverse community in its training and employment programs.